17.16 -0.34 (-1.99%)
IPXL
Stock Details
Last Trade:17.16 Change:-0.34 (-1.99%) Prev Close:17.50 Open: 17.10 Days Range:16.97 – 17.34 52 Week Range: 4.68 - 17.75 Volume:1077275 P/E: 20.93EPS:0.82
View AllRecent Alerts 03/18/10
Recent Alert on 03/18/10 at 8:36am
BofA/Merrill Lynch Downgrades Impax Laboratories (IPXL) to Underperform
BofA/Merrill Lynch Downgrades Impax Laboratories (IPXL) to Underperform
BofA/Merrill Lynch downgrades Impax Laboratories (Nasdaq: IPXL) from Neutral to Underperform. PT $17. To see all the upgrades/downgrades on shares of IPXL, visit our Analyst Ratings page. Impax Laboratories, Inc. is a technology-based, specialty... Read More
Recent Alert on 03/15/10 at 9:36am
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Recent Alert on 03/15/10 at 9:36am
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Impax Labs (IPXL) to Challenge Ruling on TRILIPIX Delayed-Release Capsules (ABT)
Recent Alert on 03/02/10 at 8:48am
FDA Grants Final Approval of Impax Labs' (IPXL) ANDA for Generic Version of FLOMAX 0.4mg Capsules
FDA Grants Final Approval of Impax Labs' (IPXL) ANDA for Generic Version of FLOMAX 0.4mg Capsules
Recent Alert on 03/02/10 at 8:48am
FDA Grants Final Approval of Impax Labs' (IPXL) ANDA for Generic Version of FLOMAX 0.4mg Capsules
FDA Grants Final Approval of Impax Labs' (IPXL) ANDA for Generic Version of FLOMAX 0.4mg Capsules
View AllRecent Press Releases
Press Release on 03/17/10 at 9:30am
Impax Laboratories to Present at the Barclays Capital 2010 Global Healthcare Conference
Impax Laboratories to Present at the Barclays Capital 2010 Global Healthcare Conference
Press Release on 03/15/10 at 9:30am
Impax Laboratories Confirms Patent Challenge Relating to TRILIPIX(R) Delayed-Release Capsules, 135 mg and 45 mg
Impax Laboratories Confirms Patent Challenge Relating to TRILIPIX(R) Delayed-Release Capsules, 135 mg and 45 mg
View AllRecent SEC Filings
No Recent SEC Filings Available
View AllRecent Blog Posts
Blog Posts on 03/18/10 at 3:25am
High Conviction: The Dominant Generic Drugmaker Will Widen Its Lead
High Conviction: The Dominant Generic Drugmaker Will Widen Its Lead
Blog Posts on 01/04/10 at 12:00pm
Analyst Upgrades, Downgrades and Initiations: BA, BMY, EAT, INTC, MS, UNH, WYNN ...
Analyst Upgrades, Downgrades and Initiations: BA, BMY, EAT, INTC, MS, UNH, WYNN ...